Date	:2022/7/26		
Your	Name:Ze	eyu Bi	
Man	uscript Title: Com	paring the efficacy and safety o	f tenofovir and adefovir or combined drug treatment for the
treat	ment of chronic hep	patitis B infection: a systematic	review and meta-analysis
Man	uscript number (if kı	nown):	
relate partito transfer relate The factor The atto the medical relate to the relate re	ed to the content of es whose interests nansparency and does ionship/activity/interestions in the content of th	f your manuscript. "Related" me may be affected by the content is not necessarily indicate a bias erest, it is preferable that you d apply to the author's relationsh os/activities/interests should be typertension, you should declare medication is not mentioned in	nips/activities/interests as they relate to the <u>current</u> e <u>defined broadly</u> . For example, if your manuscript pertains e all relationships with manufacturers of antihypertensive
		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the init	tial planning of the work
	All support for the pre manuscript (e.g., fund provision of study mat medical writing, article processing charges, et No time limit for this	esentXNone ling, terials, e tc.)	
		Time frame: pa	act 26 months
2	Grants or contracts fro	•	ast 50 months
	any entity (if not indic in item #1 above).		
	Royalties or licenses	XNone	
4	Consulting fees	XNone	

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	XNone	
6	Payment for expert testimony	XNone	
7	Support for attending meetings and/or travel	XNone	
8	Patents planned, issued or pending	_XNone	
9	Participation on a Data Safety Monitoring Board or Advisory Board	XNone	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	XNone	
11	Stock or stock options	XNone	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	XNone	
13	Other financial or non- financial interests	XNone	
	use summarize the above co uthor declares no conflict of in		owing box:

Date	e:2022/7/26		
	r Name: Ling Wang		
Mar	nuscript Title: Comparing	the efficacy and safety of t	enofovir and adefovir or combined drug treatment for the
trea	tment of chronic hepatitis E	B infection: a systematic re	view and meta-analysis
Mar	nuscript number (if known):		
rela part to tr rela	ted to the content of your n ies whose interests may be ransparency and does not no tionship/activity/interest, it	nanuscript. "Related" mean affected by the content of ecessarily indicate a bias. is preferable that you do	
	ronowing questions apply t nuscript only.	o the author's relationship	s/activities/interests as they relate to the <u>current</u>
to the med	ne epidemiology of hyperter lication, even if that medica	nsion, you should declare a tion is not mentioned in the port for the work reported	lefined broadly. For example, if your manuscript pertains all relationships with manufacturers of antihypertensive ne manuscript. In this manuscript without time limit. For all other items,
		Name all autities with	Specifications/Commonts
		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initia	l planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	XNone	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	XNone	
4	Consulting fees	XNone	

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	XNone	
6	Payment for expert testimony	XNone	
7	Support for attending meetings and/or travel	XNone	
8	Patents planned, issued or pending	_XNone	
9	Participation on a Data Safety Monitoring Board or Advisory Board	XNone	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	XNone	
11	Stock or stock options	XNone	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	XNone	
13	Other financial or non- financial interests	XNone	
	use summarize the above co uthor declares no conflict of in		owing box:

Dat	e:2022/7/26					
You	r Name: Huixin Hou _					
Mai	Manuscript Title: Comparing the efficacy and safety of tenofovir and adefovir or combined drug treatment for the					
trea	tment of chronic hepatitis E	infection: a systematic re	view and meta-analysis			
Mai	nuscript number (if known):					
rela par to t rela	ted to the content of your name ties whose interests may be ransparency and does not not interest, it	nanuscript. "Related" mean affected by the content of ecessarily indicate a bias. is preferable that you do				
	tollowing questions apply the strain of the	o the author's relationship	s/activities/interests as they relate to the <u>current</u>			
to t med In it	he epidemiology of hypertendication, even if that medication	nsion, you should declare a tion is not mentioned in the port for the work reported	lefined broadly. For example, if your manuscript pertains all relationships with manufacturers of antihypertensive ne manuscript. In this manuscript without time limit. For all other items,			
		Name all entities with	Specifications/Comments			
		whom you have this	Specifications/Comments (e.g., if payments were made to you or to your			
		relationship or indicate	institution)			
		none (add rows as				
		needed)				
		Time frame: Since the initia	l planning of the work			
1	All support for the present	X None				
	manuscript (e.g., funding,					
	provision of study materials,					
	medical writing, article					
	processing charges, etc.)					
	No time limit for this item.					
		Time frame: past	: 36 months			
2	Grants or contracts from	XNone				
	any entity (if not indicated					
	in item #1 above).					
3	Royalties or licenses	XNone				
4	Consulting fees	X None				

5	Payment or honoraria for lectures, presentations, speakers bureaus,	XNone	
	manuscript writing or educational events		
6	Payment for expert	XNone	
	testimony		
7	Support for attending meetings and/or travel	XNone	
	,		
8	Patents planned, issued or	_XNone	
	pending		
9	Participation on a Data	X None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	XNone	
	in other board, society, committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	XNone	
12	Receipt of equipment,	X None	
12	materials, drugs, medical	XNone	
	writing, gifts or other services		
13	Other financial or non-	XNone	
	financial interests		
Plea	ase summarize the above co	nflict of interest in the follo	owing box:
Д	author declares no conflict of in	terest.	

Dat	e:2022/7/26		
You	r Name: Miao Lu		
Maı	nuscript Title: Comparing	the efficacy and safety of t	enofovir and adefovir or combined drug treatment for the
trea	itment of chronic hepatitis E	B infection: a systematic re	view and meta-analysis
Maı	nuscript number (if known):		
rela par to t rela	ted to the content of your name ties whose interests may be ransparency and does not not interest, it	nanuscript. "Related" mean affected by the content of ecessarily indicate a bias. is preferable that you do	
	rollowing questions apply the stript only.	o the author's relationship	s/activities/interests as they relate to the <u>current</u>
IIIai	iuscript only.		
to t med In it	he epidemiology of hypertendication, even if that medication	nsion, you should declare a tion is not mentioned in the port for the work reported	lefined broadly. For example, if your manuscript pertains all relationships with manufacturers of antihypertensive ne manuscript. I in this manuscript without time limit. For all other items,
		A. II	
		Name all entities with whom you have this	Specifications/Comments (e.g., if payments were made to you or to your
		relationship or indicate	institution)
		none (add rows as	Institution
		needed)	
		Time frame: Since the initia	l planning of the work
1	All support for the present	X None	
_	manuscript (e.g., funding,		
	provision of study materials,		
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: past	: 36 months
2	Grants or contracts from	XNone	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	XNone	
4	Consulting fees	X None	

5	Payment or honoraria for lectures, presentations, speakers bureaus,	XNone	
	manuscript writing or educational events		
6	Payment for expert	XNone	
	testimony		
7	Support for attending meetings and/or travel	XNone	
	,		
8	Patents planned, issued or	_XNone	
	pending		
9	Participation on a Data	X None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	XNone	
	in other board, society, committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	XNone	
12	Receipt of equipment,	X None	
12	materials, drugs, medical	XNone	
	writing, gifts or other services		
13	Other financial or non-	XNone	
	financial interests		
Plea	ase summarize the above co	nflict of interest in the follo	owing box:
Д	author declares no conflict of in	terest.	

Date	e:2022/7/26					
You	r Name: Wei Wang _					
Mar	Manuscript Title: Comparing the efficacy and safety of tenofovir and adefovir or combined drug treatment for the					
trea	tment of chronic hepatitis B	B infection: a systematic re	view and meta-analysis			
Mar	nuscript number (if known):					
rela part to ti rela	ted to the content of your n ies whose interests may be ransparency and does not no tionship/activity/interest, it	nanuscript. "Related" mean affected by the content of ecessarily indicate a bias. is preferable that you do	relationships/activities/interests listed below that are ns any relation with for-profit or not-for-profit third the manuscript. Disclosure represents a commitment If you are in doubt about whether to list a so.			
	nuscript only.	o the author's relationship	syactivities/interests as they relate to the <u>current</u>			
ıııaı	iuscript offig.					
to tl med In it	ne epidemiology of hypertentication, even if that medica	nsion, you should declare a tion is not mentioned in the port for the work reported	lefined broadly. For example, if your manuscript pertains all relationships with manufacturers of antihypertensive ne manuscript. In this manuscript without time limit. For all other items,			
		Alama all analista andala	Constitution (Community			
		Name all entities with	Specifications/Comments			
		whom you have this relationship or indicate	(e.g., if payments were made to you or to your institution)			
		none (add rows as	institution			
		needed)				
		Time frame: Since the initia	planning of the work			
1	All support for the present	X None				
_	manuscript (e.g., funding,					
	provision of study materials,					
	medical writing, article					
	processing charges, etc.)					
	No time limit for this item.					
		Time frame: past	36 months			
2	Grants or contracts from	XNone				
	any entity (if not indicated					
2	in item #1 above).	V N				
3	Royalties or licenses	XNone				
4	Consulting fees	X None				

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	XNone	
6	Payment for expert testimony	XNone	
7	Support for attending meetings and/or travel	XNone	
8	Patents planned, issued or pending	_XNone	
9	Participation on a Data Safety Monitoring Board or Advisory Board	XNone	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	XNone	
11	Stock or stock options	XNone	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	XNone	
13	Other financial or non- financial interests	XNone	
	use summarize the above co uthor declares no conflict of in		owing box:

Date	:2022/7/26				
	· Name: Zishuo Li				
Man	Manuscript Title: Comparing the efficacy and safety of tenofovir and adefovir or combined drug treatment for the				
treat	tment of chronic hepatitis B	infection: a systematic re	view and meta-analysis		
Man	uscript number (if known):				
relate partito transcriptor transcriptor the state of the med	ted to the content of your name ies whose interests may be ansparency and does not not ionship/activity/interest, it following questions apply touscript only. author's relationships/activite epidemiology of hyperterication, even if that medical	nanuscript. "Related" mea affected by the content of ecessarily indicate a bias. is preferable that you do the author's relationship rities/interests should be on sion, you should declare a tion is not mentioned in the port for the work reported	os/activities/interests as they relate to the <u>current</u> defined broadly. For example, if your manuscript pertains all relationships with manufacturers of antihypertensive		
		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)		
		Time frame: Since the initia	I planning of the work		
1	All support for the present	X None	n planning of the work		
1	manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.				
		Time frame: past	t 36 months		
2	Grants or contracts from	XNone			
	any entity (if not indicated in item #1 above).				
3	Royalties or licenses	X None			
5	noyalties of ficelises	NUITE			
1	Consulting fees	Y None			

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	XNone	
6	Payment for expert testimony	XNone	
7	Support for attending meetings and/or travel	XNone	
8	Patents planned, issued or pending	_XNone	
9	Participation on a Data Safety Monitoring Board or Advisory Board	XNone	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	XNone	
11	Stock or stock options	XNone	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	XNone	
13	Other financial or non- financial interests	XNone	
	use summarize the above co uthor declares no conflict of in		owing box:

Date	e:2022/7/26				
You	r Name: Chengjiang Liu				
Manuscript Title: Comparing the efficacy and safety of tenofovir and adefovir or combined drug treatment for the					
trea	tment of chronic hepatitis E	3 infection: a systematic re	view and meta-analysis		
Man	uscript number (if known):				
In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so. The following questions apply to the author's relationships/activities/interests as they relate to the current manuscript only. The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript. In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.					
		Name all entities with whom you have this relationship or indicate none (add rows as	Specifications/Comments (e.g., if payments were made to you or to your institution)		
		needed)	Interming of the work		
1	All accompant for the contract	Time frame: Since the initia	I planning of the work		
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	XNone			
		Time frame: past	36 months		
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone			
3	Royalties or licenses	XNone			
4	Consulting fees	X None			

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	XNone	
6	Payment for expert testimony	XNone	
7	Support for attending meetings and/or travel	XNone	
8	Patents planned, issued or pending	_XNone	
9	Participation on a Data Safety Monitoring Board or Advisory Board	XNone	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	XNone	
11	Stock or stock options	XNone	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	XNone	
13	Other financial or non- financial interests	XNone	
	use summarize the above co uthor declares no conflict of in		owing box: